

LITERATURA

1. AISLP. Automatizovaný informační systém humánních, homeopatických a veterinárních léčivých přípravků registrovaných v České republice a na Slovensku. <http://www.aislp.cz>
2. Anděl I. Vyšetřovací postup u pacientů s benigní hyperplazií prostaty. *Urol Listy* 2004;4:30–34.
3. Anderson JB, Roehrborn CG, Schalken JA et al. The progression of benign prostatic hyperplasia: examining the evidence and determining the risk. *Eur Urol* 2001;39(4):390–399.
4. AUA. American Urological Association guidelines on the management of benign prostatic hyperplasia, 2003. <http://www.auanet.org>
5. AUA Benign prostate hyperplasia (BPH). A patient's guide, 2003. <http://www.auanet.org>
6. Barkin J, Guimaraes M, Jacobi G et al. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the use of dual 5-alpha reductase inhibitor dutasteride. *Eur Urol* 2003;44(4):461–466.
7. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostate hyperplasia with age. *J Urol* 1984;121:474.
8. Berry MJ, Fowler FJ, O'Leary MP, et al. Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of American Urological Association, *Med Care* 1995.
9. Brown TC, van der Meulen J, Mundy AR et al. Defining the components of a self-management programme for men with uncomplicated lower urinary tract symptoms: A consensus approach. *Eur Urol* 2004;46:254–263.
10. Bruskewitz R, Girman CJ, Rowler J et al. Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group (Proscar LongTerm Efficacy and Safety Study). *Urology* 1999;54(4):670–678.
11. Denis L, Mc Connell J, Khoury S et al. Recommendations of the International Scientific Committee: The evaluation and treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction. In: Proceedings of the international consultation on benign prostatic hyperplasia, United Kingdom. Health Publication Ltd. 1998:669–684.
12. Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. *Eur Urol* 1988;36:1–13.
13. de la Rosette J, Madersbacher S, Alivizatos G et al. Guidelines on benign prostatic hyperplasia. EAU December 2004. *Urol Listy* 2004;4:71–103. http://www.uroweb.org/files/uploaded_files/BPHDec2004webversion.pdf
14. EAU Guidelines Pocket Edition 3, Benign Prostatic Hyperplasia Board EAU, Healthcare Office, 2004.

15. Flanigan RC, Reda DI, Wasson JH et al. 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. *J Urol* 1998;160(1):12–17.
16. Hanuš M. Benigní hyperplazie prostaty a terapie alfablokátory. *Urol pro Praxi* 2001;2:186–200.
17. Hora M. Fytopreparáty v léčbě BHP. *Urol Listy* 2004;4:42–45.
18. Hanno PM, Malkowicz SB, Wein AJ. Clinical manual of urology. McGraw-Hill, New York 2001; p. 437–470.
19. Chapple CR, Al-Shkri SH, Gattegno B et al. Tamsulosin oral controlled absorption system (TOCAS) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH). Efficacy and tolerability in a placebo ad active comparator controlled phase 3 a study. *Eur Urol* 2005;4:33–44.
20. Chute CG, Panser LA, Girman CJ et al. The prevalence of prostatism: a population-based survey of urinary symptoms. *J Urol* 1993;150(1):85–89.
21. IMS Health: Celkové roční prodeje léků na BHP v České republice, 2001–2003. <http://www.imshealth.com>
22. Jacobsen SJ, Jacobson DJ, Gizman CI et al. Treatment for benign prostatic hyperplasia among community dwelling men: The Olmsted County study of urinary symptoms and health status. *J Urol* 1999;162(4):1301–1306.
23. Jarolím L. Zvětšená prostata – patientská příručka. Triton, Praha 2000.
24. Kaplan SA, Slawin KM, Te AE. Benign prostatic hyperplasia: New diagnostic and treatment paradigms. AUA Annual Meeting, San Antonio 2005.
25. Kawaciuk I. O symptomatologii benigní hyperplazie prostaty. *Čes Urol* 1998;3:5–8.
26. Kawaciuk I. Urologie, učebnice pro studenty lékařských fakult. Galén, Praha 2001.
27. Kirby PS, Roehrborn CG, Boyle P et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: The prospective European doxazosin and combination therapy (PREDICT) trial. *Urology* 2003;61(61):119–126.
28. Lepor H, Lowe FC. Evaluation and nonsurgical management of benign prostatic hyperplasia. In: Walsh PC. Campbell's Urology, 8. vydání. WB Saunders, Philadelphia 2002; p. 1337–1378.
29. Marberger M, Harkaway R, de la Rosette J. Optimising the medical management of benign prostatic hyperplasia. *Eur Urol* 2004;45:411–419.
30. McConnell JD, Roehrborn CG, Bautista OM et al. The long-term effect of doxazosin, finasteride and combination therapy on the clinical progression of BPH (MTOPS). *N Engl J Med* 2003;249(349):2385–2396.
31. Mitropoulos D, Anastasio I, Giannoupoulou C et al. Symptomatic benign prostate hyperplasia: impact on partner's quality of life. *Eur Urol* 2002;41: 240–245.
32. Morávek P. Současný stav diagnostiky a léčby BHP v České republice (přehledový článek). *Čes Urol* 2002;6:23–25.
33. NHAMCS. National hospital ambulatory medical care survey – ER files. 1994, 1996, 1998, 2000, 2002 (CD-ROM).
34. PDR Electronic Library. Physician Desk Reference 2004. Thomson Medical Economics. CD-ROM.
35. Perachino M. Information to the patient: What must be said concerning the natural history and treatment of BPH. *EAU Update Series* 2004;2:34–39.

36. Polascik TJ, Oesterlin JE, Partin AW. Prostatic specific antigen: a decade of discovery – what we have learned and where we are going. *J Urol* 1999; 172:293.
37. Roehrborn CG, Boyele P, Bergner D et al. Serum prostate-specific antigen and prostate volume predict long-term change in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. *Urology* 1999;54(4):662–669.
38. Roehrborn CG, Malice M, Cook TJ et al. Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the placebo groups of several large clinical trials. *Urology* 2001;210:58.
39. Roehrborn CG, McConnell JD. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In: *Campbell's Urology*. WB Saunders, Philadelphia 2002;38:1297–1330.
40. Roehrborn CG, Lepor H, Kirby R. Pharmacologic therapy of BPH. AUA Annual meeting, San Francisco 2004.
41. Roehrborn CG, Lepor H, Kirby R. Medical therapy for lower urinary tract symptoms and BPH. AUA Annual Meeting, San Antonio 2005.
42. Schwinn DA. The role of alpha-1-adrenergic receptor subtypes in lower urinary tract symptoms. *Br J Urol* 2001;88:27–34.
43. Šafařík L, Povýšil C. Benigní hyperplazie prostaty. In: Dvořáček J et al. *Urologie (díl II)*; s. 1195–1252.
44. Šebek T. Benigní hyperplazie prostaty, informace pro pacienty. <http://www.zdravcentra.cz>
45. Tanagho EA, McAninch JW. *Smith's General Urology*, 16. vydání. Lange Medical Books/McGraw Hill, New York 2004; p. 367–374.
46. Verhamme KMC, Dieleman JP, Bleumink GS et al. Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: The Triumph Project. *Eur Urol* 2003;44:539–545.
47. Verner P. Zobrazovací metody. In: Hanuš M. *Interaktivní urologie*, 2003. <http://www.zdravcentra.cz>
48. Verner P. Benigní hyperplazie prostaty. *Remedia* 2004;24(4):346–354.
49. Wei JT, Cahou EA, Jacobsen SJ. Benign prostatic hyperplasia. *Eur Pharmacother* 2004; p. 43–67.